Chemistry Reference
In-Depth Information
[18] Leach, A. R., Hann, M. M., Burrows, J. N., Griffen, E. Fragment screening: an introduction. In
Structure-based Drug Discovery
, ed. Hubbard, R. E., Royal Society of Chemistry, Cambridge,
2006, pp. 142-172.
[19] Hann, M. M., Leach, A. R., Harper, G. Molecular complexity and its impact on the probability
of finding leads for drug discovery.
J. Chem. Inf. Comput. Sci.
2001,
41
, 856-864.
[20] Teague, S. J., Davis, A. M., Leeson, P. D., Oprea, T. The design of leadlike combinatorial
libraries.
Angew. Chem. Int. Ed.
1999,
38
, 3743-3748.
[21] Makara, G. M. On sampling of fragment space.
J. Med. Chem.
2007,
50
, 3214-3221.
[22] Rees, D. C., Congreve, M., Murray, C. W., Carr, R. Fragment-based lead discovery.
Nat. Rev.
Drug Discov.
2004,
3
, 660-672.
[23] Fattori, D. Molecular recognition: the fragment approach in lead generation.
Drug Discov. Today
2004,
9
, 229-238.
[24] Hajduk, P. J., Greer, J. A decade of fragment-based drug design: strategic advances and lessons
learned.
Nat. Rev. Drug Discov.
2007,
6
, 211-219.
[25] Jahnke,W., Erlanson, D.A.
Fragment-basedApproaches in Drug Discovery
,Wiley-VCHVerlag
GmbH, Weinheim, 2006.
[26] Jhoti, H., Cleasby, A., Verdonk, M., Williams, G. Fragment-based screening using X-ray
crystallography and NMR spectroscopy.
Curr. Opin. Chem. Biol.
2007,
11
, 485-493.
[27] Zartler, E. R., Mo, H. Practical aspects of NMR-based fragment discovery.
Curr. Top. Med.
Chem.
2007,
7
, 1592-1599.
[28] Lepre, C. A., Moore, J. M., Peng, J. W. Theory and applications of NMR-based screening in
pharmaceutical research.
Chem. Rev.
2004,
104
, 3641-3675.
[29] Coles, M., Heller, M., Kessler, H. NMR-based screening technologies.
Drug. Discov. Today
2003,
8
, 803-810.
[30] Geschwindner, S., Olsson, L.-L.,Albert, J. S., Deinum, J., Edwards, P. D., de Beer, T., Folmer, R.
H.A. Discovery of aNovel warhead against -secretase through fragment-based lead generation.
J. Med. Chem.
2007,
50
, 5903-5911.
[31] Dalvit, C., Pevarello, P., Tato, M., Veronesi, M., Vulpetti, A., Sundstrom, M. Identification
of compounds with binding affinity to proteins via magnetization transfer from bulk water.
J. Biomol. NMR
2000,
18
, 65-68.
[32] Dalvit, C., Fogliatto, G., Stewart, A., Veronesi, M., Stockman, B. WaterLOGSY as a method for
primary NMR screening: practical aspects and range of applicability.
J. Biomol. NMR
2001,
21
,
349-359.
[33] Ghosh, A. K., Shin, D., Downs, D., Koelsch, G., Lin, X., Ermolieff, J., Tang, J. Design of potent
inhibitors for human brain memapsin 2 (-secretase).
J. Am. Chem. Soc.
2000,
122
, 3522-3523.
[34] Cooper, M. A. Optical biosensors: where next and how soon?
Drug. Discov. Today
2006,
11
,
1061-1067.
[35] Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey,
H. F., Frigon, N., Hong, J., Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J., Lieberburg, I.,
Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D., Seubert, P., Suomensaari, S. M., Wang, S.,
Walker, D., Zhao, J., McConlogue, L., John, V. Purification and cloning of amyloid precursor
protein -secretase from human brain.
Nature
1999,
402
, 537-540.
[36] Karlsson, R., Kullman-Magnusson, M., Hamalainen, M. D., Remaeus, A., Andersson, K., Borg,
P., Gyzander, E., Deinum, J. Biosensor analysis of drug-target interactions: direct and compet-
itive binding assays for investigation of interactions between thrombin and thrombin inhibitors.
Anal. Biochem.
2000,
278
, 1-13.
[37] Abad-Zapatero, C. Ligand efficiency indices for effective drug discovery.
Expert Opin. Drug
Discov.
2007,
2
, 469-488.
[38] Hopkins, A. L., Groom, C. R., Alex, A. Ligand efficiency: a useful metric for lead selection.
Drug. Discov. Today
2004,
9
, 430-431.
